Histone deacetylase inhibitors (HDACi) can elicit a range of biological responses that
impede the growth and/or survival of tumor cells. Depending on the physiological context …

Histone deacetylase inhibitors (HDIs) are a promising new class of antineoplastic agents
with the capacity to induce growth arrest and/or apoptosis of cancer cells. However, their …

Anomalous gene regulation, dictated by epigenetic modifications, is a universal
characteristic of cancer cells. Histone deacetylases (HDACs) are an important class of …

Romidepsin and vorinostat are histone deacetylase inhibitors (HDACis) that have activity in
T-cell lymphomas, but have not gained traction in solid tumors. To gain deeper insight into …

Epigenic modifications, mainly DNA methylation and acetylation, are recognized as the main
mechanisms contributing to the malignant phenotype. Acetylation and deacetylation are …

This review focuses on the mechanisms of action of histone deacetylase (HDAC) inhibitors
(HDACi), a group of recently discovered 'targeted'anticancer agents. There are 18 HDACs …

The histone deacetylase inhibitors (HDACi) have demonstrated anticancer efficacy across a
range of malignancies, most impressively in the hematological cancers. It is uncertain …

It has been shown that epigenetic modifications play an important role in tumorigenesis.
Thus, affecting epigenetic tumorigenic alterations can represent a promising strategy for …

Histone deacetylases (HDACs) regulate transcription and specific functions, such as tumor
suppression by p53, and are frequently altered in cancer. Inhibitors of HDACs (HDACI) …

Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin
remodeling and have crucial roles in numerous biological processes, largely through their …